Amylyx posts late-stage trial win for GLP-1 drug (AMLX:NASDAQ)
· seekingalpha.com
Amylyx Pharmaceuticals (AMLX) stock is expected to rise as the company reports a late-stage trial win for its GLP-1 receptor antagonist avexitide. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...